Overall, in contrast to its key function in AML (both MLL-r and AML-ETO) and DLBCL, CARM1 appears to play a modest role in normal HSPC differentiation and proliferation (82), which indicates a favorable therapeutic value for CARM1 inhibitors in hematological malignancies. Here, RUNX1T1 is linked to acute myeloid leukemia.